What happened
Immunic, Inc. (NASDAQ: IMUX) reported a third-quarter net loss of $42.3 million, up from $25.6 million a year earlier.
The company said its Phase 3 ENSURE-1 and ENSURE-2 trials of vidofludimus calcium in relapsing multiple sclerosis remain on track to report top-line data in December 2026. If the results are positive, Immunic plans to file a New Drug Application in the United States in mid-2027.
Loss per share narrowed to $0.99 from $1.32. The weighted-average share count more than doubled, to 42.8 million from 19.4 million.
Explain the financial terms
A fiscal quarter is a three-month period in the company's reporting year.
Why it matters
By OptimistFi's calculation, the net loss widened 65.4%, and most of that comes from one line. General and administrative expenses rose to $19.4 million from $6.0 million, a $13.4 million increase.
OptimistFi treats Immunic as a financing-sensitive bet that late-stage data can outweigh cash burn and dilution. The quarter points both ways. Cash is enough to reach the December readout, but the cost base is heavier.
The filing warns that earlier post-hoc, exploratory, open-label or preclinical analyses may not predict results in controlled trials or win regulator acceptance. It also says the ENSURE results may be delayed, negative or miss their endpoints.
Explain the financial terms
A fiscal quarter is a three-month period in the company's reporting year.
Where the spending went
Operating expenses reached $43.4 million, against $26.0 million in the third quarter of 2025. Of the G&A increase, $9.7 million was non-cash stock compensation, mostly tied to a separation agreement. Legal and consultancy costs rose $1.3 million and pre-commercial marketing expenses rose $0.6 million.
For the whole quarter, $13.9 million of operating expenses were non-cash charges, mainly stock compensation. Without them, operating expenses were $29.5 million, by OptimistFi's calculation.
Research and development expenses rose 19.7% to $23.9 million from $20.0 million. NDA readiness activities added $2.9 million and vidofludimus calcium drug supply added $1.4 million. A $1.8 million drop in ENSURE trial costs offset part of that.
Immunic also created two executive roles to support regulatory and commercial readiness. A Chief Data and Digital Officer started Sept. 1 and a Chief People Officer started Oct. 19.
Over nine months, the net loss was $109.0 million, up from $77.9 million. Operating expenses were $111.9 million, including $25.2 million of non-cash charges.
Explain the financial terms
A fiscal quarter is a three-month period in the company's reporting year.
Cash and runway
Cash and cash equivalents stood at $132.0 million on Sept. 30, up from $15.5 million at Dec. 31, 2025. Interest income rose to $1.1 million from $0.4 million a year earlier. The filing ties that to a higher average cash balance after the February 2026 Private Placement.
Immunic expects the cash to fund operations into late 2027 based on its current operating plan. It targets possible regulatory approval in 2028 if the ENSURE results are positive, so the stated runway ends before that date. The filing also lists a risk that cash may prove insufficient and that Immunic may need to raise more capital.
What's next
The next test is the December top-line data from ENSURE-1 and ENSURE-2, which randomized 1,121 and 1,100 patients at more than 100 sites in 15 countries. Positive results would support the NDA plan. A delay or a miss on the endpoints would undercut it.
Separately, the first patient is expected to enroll in the Phase 3 PROTECT-MS trial in progressive MS in the first half of 2027.